文献速递糖尿病肥胖与代谢综合征

遗传 Proxy 的降糖药物靶点扰动与癌症风险:一项孟德尔随机化分析

Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis.
PubMed 文献 · Diabetologia · 2023-05-12

研究利用百万退伍军人计划中2型糖尿病(148,726例病例和965,732例对照)的遗传数据构建PPARG、ABCC8和GLP1R的遗传工具,在乳腺癌、结直肠癌、前列腺癌及总体癌症的GWAS汇总数据中进行孟德尔随机化分析,未发现一致的证据支持这些靶点扰动与癌症风险相关。

要点

  • 遗传 Proxy 的 PPARG 扰动与前列腺癌风险 weakly 相关:OR 1.75(95%CI 1.07,2.85),p=0.02。
  • 遗传 Proxy 的 PPARG 扰动与 ER 阳性乳腺癌风险 weakly 相关:OR 0.57(95%CI 0.38,0.85),p=6.45×10-3。
  • 未发现 ABCC8 或 GLP1R 扰动与各癌症终点风险相关的证据。

核心结论

  • 药物靶点孟德尔随机化分析未发现一致证据支持遗传 Proxy 的 PPARG、ABCC8 或 GLP1R 扰动与乳腺癌、结直肠癌、前列腺癌或总体癌症风险相关。
  • 作者认为采用替代分子流行病学方法进一步评估这些药物靶点可能有助于进一步证实本分析的结果。

研究设计与样本

  • 利用百万退伍军人计划中2型糖尿病全基因组关联研究的汇总遗传关联数据(148,726例病例和965,732例对照)构建三种降糖药物靶点(PPARG、ABCC8、GLP1R)的遗传工具。
  • 遗传工具使用顺式作用的全基因组显著(p<5×10-8)SNP,允许处于弱连锁不平衡(r2<0.20)。
  • 从乳腺癌(122,977例病例和105,974例对照)、结直肠癌(58,221例病例和67,694例对照)、前列腺癌(79,148例病例和61,106例对照)及总体癌症(27,483例病例和372,016例对照)的GWAS联盟获取这些SNP的汇总遗传关联估计。
  • 采用逆方差加权随机效应模型并校正连锁不平衡估计遗传 Proxy 的药物靶点扰动与癌症风险之间的因果关联。
  • 采用共定位分析检验结果对孟德尔随机化假设违反的稳健性,并使用 Bonferroni 校正作为启发式方法将孟德尔随机化分析的关联定义为「强」和「弱」证据。

主要发现

  • 在孟德尔随机化分析中,遗传 Proxy 的 PPARG 扰动与前列腺癌风险 weakly 相关:对于相当于逆秩正态转换 HbA1c 降低1个单位的 PPARG 扰动,OR 1.75(95%CI 1.07,2.85),p=0.02。
  • 在组织学亚型分层分析中,遗传 Proxy 的 PPARG 扰动与雌激素受体阳性乳腺癌风险 weakly 相关:OR 0.57(95%CI 0.38,0.85),p=6.45×10-3。
  • 在共定位分析中,PPARG 位点上2型糖尿病易感性与癌症终点之间共享因果变异的证据很少,但这些分析可能把握度不足。
  • 几乎没有证据支持遗传 Proxy 的 PPARG 扰动与结直肠癌或总体癌症风险相关,或遗传 Proxy 的 ABCC8 或 GLP1R 扰动与各癌症终点风险相关。

局限性

  • 共定位分析中,PPARG 位点上2型糖尿病易感性与癌症终点之间共享因果变异的证据很少,但这些分析可能把握度不足。
  • 作者认为采用替代分子流行病学方法进一步评估这些药物靶点可能有助于进一步证实本分析的结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Epidemiological studies have generated conflicting findings on the relationship between glucose-lowering medication use and cancer risk. Naturally occurring variation in genes encoding glucose-lowering drug targets can be used to investigate the effect of their pharmacological perturbation on cancer risk. METHODS: We developed genetic instruments for three glucose-lowering drug targets (peroxisome proliferator activated receptor γ [PPARG]; sulfonylurea receptor 1 [ATP binding cassette subfamily C member 8 (ABCC8)]; glucagon-like peptide 1 receptor [GLP1R]) using summary genetic association data from a genome-wide association study of type 2 diabetes in 148,726 cases and 965,732 controls in the Million Veteran Program. Genetic instruments were constructed using cis-acting genome-wide significant (p<5×10-8) SNPs permitted to be in weak linkage disequilibrium (r2<0.20). Summary genetic association estimates for these SNPs were obtained from genome-wide association study (GWAS) consortia for the following cancers: breast (122,977 cases, 105,974 controls); colorectal (58,221 cases, 67,694 controls); prostate (79,148 cases, 61,106 controls); and overall (i.e. site-combined) cancer (27,483 cases, 372,016 controls). Inverse-variance weighted random-effects models adjusting for linkage disequilibrium were employed to estimate causal associations between genetically proxied drug target perturbation and cancer risk. Co-localisation analysis was employed to examine robustness of findings to violations of Mendelian randomisation (MR) assumptions. A Bonferroni correction was employed as a heuristic to define associations from MR analyses as 'strong' and 'weak' evidence. RESULTS: In MR analysis, genetically proxied PPARG perturbation was weakly associated with higher risk of prostate cancer (for PPARG perturbation equivalent to a 1 unit decrease in inverse rank normal transformed HbA1c: OR 1.75 [95% CI 1.07, 2.85], p=0.02). In histological subtype-stratified analyses, genetically proxied PPARG perturbation was weakly associated with lower risk of oestrogen receptor-positive breast cancer (OR 0.57 [95% CI 0.38, 0.85], p=6.45×10-3). In co-localisation analysis, however, there was little evidence of shared causal variants for type 2 diabetes liability and cancer endpoints in the PPARG locus, although these analyses were likely underpowered. There was little evidence to support associations between genetically proxied PPARG perturbation and colorectal or overall cancer risk or between genetically proxied ABCC8 or GLP1R perturbation with risk across cancer endpoints. CONCLUSIONS/INTERPRETATION: Our drug target MR analyses did not find consistent evidence to support an association of genetically proxied PPARG, ABCC8 or GLP1R perturbation with breast, colorectal, prostate or overall cancer risk. Further evaluation of these drug targets using alternative molecular epidemiological approaches may help to further corroborate the findings presented in this analysis. DATA AVAILABILITY: Summary genetic association data for select cancer endpoints were obtained from the public domain: breast cancer ( https://bcac.ccge.medschl.cam.ac.uk/bcacdata/ ); and overall prostate cancer ( http://practical.icr.ac.uk/blog/ ). Summary genetic association data for colorectal cancer can be accessed by contacting GECCO (kafdem at fredhutch.org). Summary genetic association data on advanced prostate cancer can be accessed by contacting PRACTICAL (practical at icr.ac.uk). Summary genetic association data on type 2 diabetes from Vujkovic et al (Nat Genet, 2020) can be accessed through dbGAP under accession number phs001672.v3.p1 (pha004945.1 refers to the European-specific summary statistics). UK Biobank data can be accessed by registering with UK Biobank and completing the registration form in the Access Management System (AMS) ( https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access ).

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Yarmolinsky J, Bouras E, Constantinescu A, et al. Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis. Diabetologia. 2023. PMID: 37171501. doi:10.1007/s00125-023-05925-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。